<DOC>
	<DOCNO>NCT02580227</DOCNO>
	<brief_summary>The objective study evaluate effect Tranexamic Acid ( TXA ) blood loss need perioperative blood transfusion follow intertrochanteric subtrochanteric femur fracture . TXA antifibrinolytic medication prevents breakdown blood clot inhibit activation plasminogen plasmin coagulation cascade . Our hypothesis provide TXA time hospital admission decrease amount preoperative intraoperative bleeding thereby lead decrease need post-operative transfusion . This double blind , placebo control , therapeutic trial half patient randomize receive TXA time hospital admission half patient receive placebo .</brief_summary>
	<brief_title>Tranexamic Acid Intertrochanteric Subtrochanteric Femur Fractures</brief_title>
	<detailed_description>Tranexamic Acid long proven history clinical safety effectiveness Orthopaedic literature . Its use perioperative blood management total joint arthroplasty wide spread quickly become standard care . However , evidence effectiveness TXA low extremity fracture care limit . There logical expectation use TXA low extremity fracture care provide similar benefit minimize blood loss reduce transfusion requirement , base TXA 's success total joint arthroplasty , however yet validate literature . This study seek evaluate effectiveness TXA perioperative blood management within subset low extremity fracture , specifically intertrochanteric femur fracture . Hip fracture represent common orthopedic injury fragile patient population often necessitate post-operative blood transfusion thereby put patient additional risk complication . Intertrochanteric femur fracture increase risk post-operative blood transfusion compare femoral neck fracture . It presume difference blood loss two fracture type cause increase pre-operative bleeding intertrochanteric fracture secondary extracapsular nature fracture , oppose tamponade effect occur intracapsular femoral neck fracture . It therefore expect use TXA intertrochanteric femur fracture decrease perioperative bleeding lead decrease total blood loss decrease transfusion rate . Limited research show TXA effective reduce perioperative blood loss hip fracture compare placebo , effectively use joint arthroplasty . One explanation difference TXA circulating time iatrogenic fracture total joint arthroplasty give shortly , whereas intraoperative TXA administration hip fracture usually n't occur 6-48 hour initial injury . Administering TXA time hospital admission intertrochanteric femur fracture allow drug time decrease blood loss result fracture well subsequent surgical intervention .</detailed_description>
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Hip Fractures</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Femoral Fractures</mesh_term>
	<mesh_term>Blood Loss , Surgical</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Patients sustain close intertrochanteric femur fracture present Good Samaritan Regional Medical Center . Patients willing able consent participate study &gt; 18 year age Patients allergy tranexamic acid . History thromboembolic event ( pulmonary embolism , cerebral vascular accident , deep venous thrombosis ) , History renal impairment ( Cr &gt; 1.5 glomerular filtration rate &lt; 30 ) Coronary stent History hypercoagulability ( Factor V Leiden , protein C/S deficiency , prothrombin gene mutation , antithrombin deficiency , antiphospholipid antibody syndrome , lupus anticoagulant ) . Color blindness Subarachnoid hemorrhage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Tranexamic Acid</keyword>
	<keyword>Blood Transfusions</keyword>
</DOC>